Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using ...
SHELTON, Conn. and BERN, Switzerland, May 6, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (INTS) (Nasdaq: INTS), ("Intensity" or "the Company") a late-stage clinical biotechnology company focused ...
Intensity also initiated a Phase 2 study in collaboration with The Swiss Group for Clinical Cancer Research, SAKK (the "INVINCIBLE-4 Study") (NCT06358573) as part of a Phase 2/3 program evaluating ...
Peer-reviewed clinical validation, strengthened balance sheet, and disciplined execution position the Company for 2026 SHELTON, Conn., Jan. 13, 2026 /PRNewswire/ -- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback